BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BPMC

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/15	06 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/15	06 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/15	06 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/15	06 : 34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/15	06 : 32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/15	05 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/08	05 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/07	05 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/06	06 : 11	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/06	05 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/05	05 : 40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/05	05 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/04	05 : 28	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/06/01	05 : 38	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/31	07 : 01	PR Newswire (US)	Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/24	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/24	06 : 05	PR Newswire (US)	Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/18	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/18	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/16	06 : 07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/16	06 : 05	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/11	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/07	06 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/07	06 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/07	05 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/05/02	20 : 00	PR Newswire (US)	Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/04/18	21 : 00	PR Newswire (US)	Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/04/11	21 : 00	PR Newswire (US)	Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/04/05	05 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation